跳至主要内容
临床试验/JPRN-UMIN000022666
JPRN-UMIN000022666已完成未知

Application of fibrinogen concentrate (Fibrinogen HT) to uncontrollable massive bleeding - Application of Fibrinogen HT to massive bleeding

Kagoshima University Hospital, Division of blood transfusion medicine and cell therapy0 个研究点目标入组 26 人开始时间: 2016年6月8日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patient (or the patient's family) who did not give informed consent.

研究者

发起方
Kagoshima University Hospital, Division of blood transfusion medicine and cell therapy

相似试验

已完成
不适用
The use of fibrinogen concentrate to disseminated intravascular coagulation during obstetric haemorrhagedisseminated intravascular coagulation
JPRN-UMIN000010540Kyoto university Graduate School of Medicine Obstetrics and gynecology9
进行中(未招募)
不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency - NDCongenital fibrinogen deficiency ( afibrinogenemia, severe hypofibrinogenemia)MedDRA version: 9.1Level: LLTClassification code 10016075
EUCTR2007-004088-22-ITCSL BEHRING GmbH23
进行中(未招募)
不适用
Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safetyCongenital fibrinogen deficiency (afibrinogenemia, severe hypofibrinogenemia)MedDRA version: 12.0Level: LLTClassification code 10016075Term: Factor I deficiency
EUCTR2007-004088-22-DECSL Behring GmbH23
进行中(未招募)
1 期
Fibrinogen concentrate supplementation for infants undergoing heart surgery with cardiopulmonary bypass
EUCTR2013-003532-68-GBGuy's and St Thomas NHS Foundation Trust
进行中(未招募)
1 期
se of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusio- Major patient- Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation- Grade = 1 hemorrhagic symptom according to WHO - WHO classification- Body weight between 38 and 78 kg- Patient presenting with a platelet refractory state defined according to the Corrected Count Increment (CCI)- Patient affiliated to a social security schemeMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864
EUCTR2021-000990-10-FRInstitut de Cancérologie Lucien Neuwirth10